Modulation of hippocampal acetylcholine release - a potent central action of interleukin-2 by Hanisch, U.K. et al.
The Journal of Neuroscience, August 1993, 13(E): 3366-3374 
Modulation of Hippocampal Acetylcholine Release: A Potent Central 
Action of Interleukin-2 
Uwe-Karsten Han&h, David Seto, and Remi Quirion 
Douglas Hospital Research Centre, Department of Psychiatry, and Department of Pharmacology and Therapeutics, 
McGill University, Montreal, Qukbec, H4H lR3 Canada 
The potential of the T-cell growth factor interleukin-2 (IL-2) 
to modulate the release of ACh from rat hippocampus was 
studied in vitro, as a means to investigate the possible func- 
tional significance of this cytokine in the CNS. Hippocampal 
slices were superfused with Krebs’ buffer medium, and en- 
dogenous ACh released into the superfusate was measured 
using a radioenzymatic assay. Recombinant human IL-2 
present during a stimulation with 25 mr.! KCI altered, in a 
concentration-dependent manner, the evoked transmitter 
release. At a concentration of 15 U/ml (5 1 nM), IL-2 inhibited 
ACh release by more than 50% of the control level (evoked 
ACh release from the untreated contralateral hemispheres). 
Inhibition was observed within 20 min of tissue exposure to 
IL-2 and lasted for up to 1 hr. The inhibitory effect of IL-2 
was reversible since transient tissue exposure to IL-2 did 
not affect subsequent evoked ACh release. IL-2 at this con- 
centration also significantly decreased evoked ACh in fron- 
tal cortical slices, but was ineffective in the parietal cortex 
and striatum, revealing that IL-2 selectively modulates the 
release of ACh from certain, but not all, cholinergic nerve 
terminals in the CNS. At very low concentrations (1.5 mU/ 
ml, ~0.1 PM), IL-2 transiently increased hippocampal evoked 
ACh release, resulting in a biphasic dose-response profile 
with no significant effect observed at 0.015 mu/ml (I 1 fM). 
Other cytokines (IL-la, IL-3, IL-5, IL-6, interferon (u), tested 
in hippocampal slice incubations, failed to modulate ACh 
release. These results suggest that the immunoregulator IL-2 
is a potent and selective modulator of ACh release in se- 
lected regions of the rat brain, an effect apparently not shared 
with other cytokines. The potent action of IL-2 on ACh re- 
lease most likely relates to the discrete distribution of IL- 
2(-like) antigen and ‘*WL-2 binding sites in rat brain tissues 
(Lapchak et al., 1991). 
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Cytokines are signaling peptides of the immune system. 
Interleukin-2 (IL-2) was one of the first cytokines to be char- 
acterized in detail (for a review, see Hatekayama and Taniguchi, 
1991). IL-2 is predominantly synthesized by antigen- or mito- 
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gen-activated T-cells and regulates, as an autocrine/paracrine 
growth hormone, their clonal expansion. IL-2, in conjunction 
with antigen, mitogen, or anti-immunoglobulin antibodies, also 
controls B-cell proliferation and differentiation into antibody- 
secreting cells. Furthermore, by acting on cytolytic T-lympho- 
cytes, and natural killer (NK) and lymphokine-activated killer 
cells, IL-2 participates in the activation of cytotoxic immune 
responses. These diverse immunoregulatory functions are me- 
diated by specific interactions with cell membrane IL-2 recep- 
tors (IL-2R), which are composed of two moieties, IL-2R&p55/ 
Tat and IL-2R@/p70, respectively (Kuziel and Greene, 1990; 
Waldmann, 199 1). IL-2Ra and IL-2RP bind IL-2 with low (kD 
x lo-* M) and moderate (k, = 1 O-9 M) affinity; upon activation- 
induced association to the noncovalent a$-heterodimer they 
form the high-affinity IL-2 receptor complex (k, = lo-It M). 
Other putative components of the receptor/effecter complex are 
predicted that may control ligand binding and receptor-medi- 
ated IL-2 endocytosis, in addition to enzymatic activities in- 
volved in IL-2-triggered signal transduction(s). Because of its 
potent immunostimulatory properties, IL-2 has been introduced 
as an anti-tumor drug (for review, see Rosenberg, 1990) and is 
now clinically used in various immunotherapeutic strategies. 
IL-2, among other cytokines, may also act as a neuromodu- 
lator in the CNS. Regulatory functions in the nervous tissue 
have been proposed, for example, for the growth and differen- 
tiation of glial and neuronal cells as well as for the control of 
neuronal activity in the hippocampus, locus coeruleus, and cer- 
tain hypothalamic nuclei (for a review, see Merrill, 1990, 199 1; 
Nisticb and De Sarro, 199 1; Plata-Salaman, 1991). As a mod- 
ulator of the neuroendocrine system, IL-2 can directly alter the 
release of pituitary hormones (Karanth and McCann, 1991). 
The presence of biological activities as well as IL-2(-like) im- 
munoreactive material (IRM), IL-2R-associated IRM, IL-2 
mRNA, and ‘251-IL-2 binding sites has been demonstrated in 
the rodent and, partly, in the human brain, under normal and 
pathophysiological conditions (Nieto-Sampedro and Chandy, 
1987; Luber-Narod and Rogers, 1988; Araujo et al., 1989; Mer- 
rill, 1990; Lapchak et al., 1991; Villemain et al., 1991). More- 
over, IL-2-induced disruption and penetration of the blood- 
brain barrier has been subject to experimental studies and clin- 
ical observation (Ellison et al., 1987, 1990; Saris et al., 1988; 
Alexander et al., 1989; Watts et al., 1989; Banks et al., 1991; 
Ellison and Merchant, 199 1). It thus appears that effects of IL-2 
in the brain could be due to the genuine existence of IL-2(-like) 
peptides intrinsic to the CNS, or to elevated blood-borne IL-2. 
Elevated amounts of peripheral IL-2 in patients undergoing 
high-dose IL-2 immunotherapy are reflected by IL-2 concen- 
trations in the cerebrospinal fluid reaching up to 9 U/ml (Saris 
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et al., 1988). At these concentrations, IL-2 immunotherapy is 
accompanied by a variety of side effects, including adverse neu- 
rologic symptoms such as memory impairments (Denicoff et 
al., 1987; Plata-Salaman, 1991). The hippocampus, a brain 
structure enriched with IL-2/IL-2R IRM, ‘251-IL-2 binding sites 
(Lapchak et al., 199 l), and IL-2 mRNA (Villemain et al., 199 l), 
is most probably involved in certain aspects of memory and 
therefore one of the likely targets of CNS-directed IL-2 activi- 
ties. Of the various neurotransmitters present in the hippocam- 
pal formation, ACh is the candidate that has most often been 
related to learning and memory. 
The objective of the present study was thus to investigate the 
potential of IL-2 to modulate ACh release in the rat hippocam- 
pal formation using in vitro brain slice superfusion. The results 
indicate that IL-2 is able to modify in a concentration-dependent 
manner ACh release in the hippocampus. Its minimal effective 
dose being in the (sub)picomolar range, it demonstrates that 
IL-2 is one of the most potent modulators of ACh release char- 
acterized so far. This effect seems to be specific, since various 
other cytokines tested failed to alter ACh release. 
Parts of the results have recently been presented in abstract 
form (Set0 et al., 1991). 
Materials and Methods 
Male albino Sprague-Dawley rats (300-325 gm) were obtained from 
Charles River (breeding colony St. Constant, Quebec, Canada). Recom- 
binant human IL-2 (rhIL-2) frequently shown to be effective in the rat 
CNS (see Karanth and McCann, 199 l), was from Sigma Chemical Co. 
(catalog number T-3267; St. Louis, MO). Interferon cy (rhIFNol) was 
from Janssen/Cedarlane Laboratories (Homby, Ontario, Canada). All 
other cytokines, in the human recombinant form (IL-la, IL-3, IL-5, 
and IL-6), were obtained from Upstate Biotechnology (Lake Placid, 
NY). Adenosine triphosphate (ATP), dithiothreitol, and bovine serum 
albumin (BSA) were from Boehringer Mannheim (Laval, Quebec, Can- 
ada): choline kinase (ATP:choline phosphotransferase, EC 2.7.1.32) 
acetylcholinesterase type V-S (acetylcholine hydrolase, EC 3.1.1.7) ace- 
tylcholine chloride, physostigmine sulfate, and Amberlite CG-400 (chlo- 
ride form) were from Sigma Chemical Co. (St. Louis, MO); tetraphen- 
ylboron and butyronitrile were from Aldrich Chemical Co. (Milwaukee, 
WI): T-‘~P-ATP (2-10 mCi/mmol) was from New Enaland Nuclear 
(Missi’ssauga, Ontario, Canada); Ecolite was from ICN (Montreal, Que- 
bec, Canada). All other chemicals were of analytical grade and purchased 
from Fisher Scientific (Montreal, Quebec, Canada). 
Tissue preparation and release studies. Rats were decapitated and the 
brains were removed into chilled Krebs’ buffer medium (KBM) com- 
oosed of (in mM) NaCI. 120: KCI. 4.6: CaCl,. 2.4: KH,PO,. 1.2: MaSO,. 
i.2; n-glucose, 9.9; Na’HCd,, 251 saturated~with’O,lCO, (95%:5%j, and 
adjusted to pH 7.4. Tissue regions (hippocampus, striatum, frontal, or 
parietal cortex) were rapidly dissected on ice and sliced at 400 pm 
intervals with a McIlwain tissue chopper. Slices of one hemisphere were 
immediately placed in a superfusion chamber, built according to Richter 
(1976), and superfused at a rate of 0.5 ml/min with KBM containing 
choline chloride (10 NM), to support synthesis of ACh, and physostig- 
mine (30 PM for the hemisulfate), to prevent enzymatic degradation of 
ACh. The buffer reservoir was continuously bubbled with O,/CO, (95%: 
5%) mixture. The temperature of the chambers and the medium was 
kept at 37°C. After 45 min, superfusate fractions (10 or 20 min each) 
were collected. Aliquots were spun in a microcentrifuge (Biofuge B 13, 
Heareus, 13,000 rpm, 3 min), and 1.3 ml of the supematant was stored 
at -70°C until further processing. Tissue slices were stimulated with 
KBM containing 25 mM KC1 (K+ KBM), with equimolar reduction in 
NaCl, in the presence of IL-2. Controls were stimulated in parallel with 
K+ KBM omitting the interleukin. At the end of the superfusion, tissue 
slices were removed from the chambers and protein content was mea- 
sured in triplicate according to Lowry et al. (195 I), using BSA dissolved 
quently, slices of one hemisphere were incubated in 1.35 ml of KBM 
containing BSA (1 mg/ml) and one of the following cytokines: IL- 1 (Y, 
IL-3, IL-5 IL-6, or IFNcr. After 20 min, the slices were incubated for 
another 20 min with the cytokine dissolved in K+ KBM containing 
BSA (1 mg/ml). As controls, slices from the contralateral hemisphere 
were treated in parallel, but in the absence of the cytokine. Supematants 
and tissues were separated by centrifugation and treated as described 
for the superfusions. 
Determination of ACh. ACh was determined using a radioenzymatic 
assay (Goldberg and McCaman, 1973). Briefly, ACh was extracted from 
samples by mixing an aliquot of 400 ~1 with an equal volume of tetra- 
phenylboron in butyronitr!ile (10 gm/liter). Separation of the phases was 
completed by centrifugation (Biofuge B 13, Heareus, 13,000 rpm, 4 
min); 300 ~1 of the organic phase was removed and shaken (4 min) with 
a half-volume of AgNO, solution (20 gm/liter). The mixture was spun 
(Biofuge B 13, Heareus, 13,000 rpm, 4 min), and 110 ~1 of the aqueous 
phase was placed in a new tube containing 10 ~1 MgCl, solution (1 M). 
After shaking and spinning, 100 ~1 of the supematant was transferred 
into a glass tube and evaporated. The pellet was dissolved in 32 ~1 of 
a reaction mixture comnosed of choline kinase (0.005 U), ATP (0.8 
mM), M&l, (12.5 mM), and dithiothreitol(5 mM) in glycylglycine buffer 
(25 ‘b-~~,-pfi 8.0). Following 30 min of incubation at30”Cj 10 ~1 of 32P- 
ATP solution (0.45 uCi) containina acetvlcholinesterase (2 U) was added 
to the sample: The ‘mixture was i&ubaied for another 30 min at 30°C. 
The reactions were terminated by addition of 100 ~1 NaOH (50 mM). 
As a result, only the choline derived from ACh was 32P-phosphorylated. 
The samples were placed on glass pipette columns filled with Amberlite 
CG-400 (approximately 800 pl bed volume) that was converted to its 
formate form and equilibrated with NaOH (50 mM). The columns were 
rinsed with 3 ml of NaOH (50 mM) to elute any phosphocholine, while 
excessive 32P-ATP (accounting for more than 99% of the activity added) 
was retained on the column. The eluate, collected in scintillation vials, 
was mixed with scintillation cocktail, and radioactivity was measured 
by liquid scintillation spectrometry. Standards of ACh chloride (O-400 
pmol in 400 ~1 of KBM) were processed in parallel. All determinations 
were carried out in triplicate. 
Calculations and statistics. Concentrations aiven for IL-2 on the basis 
of biological activity refer to BRMP units. Approximative molar con- 
centrations were calculated from the specific activity. Evoked trans- 
mitter release during superfusions was expressed as pmol ACh/min/mg 
protein and regarded as the net transmitter release over basal efllux. 
The basal efflux was determined from the superfusate samples collected 
prior, between, as well as following periods of K+ stimulations, respec- 
tively, depending on the experimental paradigm. To calculate the evoked 
release during a depolarization, the baseline was estimated for this pe- 
riod, and the values obtained for the basal efflux were subtracted from 
the total amount ofACh found in the superfusate. Statistical evaluations 
were carried out using the program NCSS (parallel or paired, two-tailed) 
t test, respectively, following F test, P ~0.05 being considered signifi- 
cant. 
Results 
Stimulation of ACh release from brain slices was carried out 
with 25 mM KCl, increasing the total concentration of K+ in 
the medium from 5.8 to 26.2 mM. At this concentration, evoked 
release is known to be at submaximal level (Lipton, 1985; Pearce 
et al., 199 1). Submaximal stimulation was regarded appropriate 
to reveal both drug-dependent attenuation as well as augmen- 
tation of the evoked transmitter release. Figure 1 shows the 
hippocampal release profile for endogenous ACh as determined 
for a stimulation period of 60 min. The average basal release 
was 0.98 f 0.29 pmol/min/mg protein (mean f SEM, n = 98). 
The average decline of the baseline value was determined to be 
1.1 %/hr (n = 18) demonstrating the stability and viability of 
the tissue preparations under the present incubating conditions. 
Effects of IL-2 on hippocampal ACh release 
in KBM as a standard. 
Evoked release of ACh from hippocampal slices was also determined 
in tissue incubations carried out according to Araujo et al. (1989). Brief- 
ly, hippocampal slices (300 pm) were incubated at 37°C in KBM (1 ml) 
for 70 mitt, with changes of the medium after 30 and 60 min. Subse- 
The effect of IL-2 on the evoked hippocampal ACh release is 
displayed in Table 1 for various times of tissue exposure to the 
interleukin. Hippocampal slices were first superfused with nor- 
ma1 KBM for 60 min to establish the basal release. Subsequent- 
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Figure 1. K+-evoked hippocampal ACh release using in vitro slice 
superfusion. Slices were superfused with normal KBM and then stim- 
ulated for 60 min with KBM containing 25 mM KC1 (K+ ). Data rep- 
resent the mean -+ SEM of 36 superfusions. 
ly, the tissue was stimulated for up to 60 min with K+ KBM 
containing various concentrations of IL-2. The ACh release in 
the presence of IL-2 was compared to controls that were stim- 
ulated in the absence of IL-2. 
Figure 2 represents an overlay of the concentration-response 
relations obtained from the various intervals of tissue stimu- 
lation, revealing the time dependency of the IL-2-mediated ef- 
fects. The augmentation of ACh release by IL-2 at 1.5 mu/ml 
was obvious during the early period of stimulation and atten- 
uated rapidly with time. On the contrary, the inhibition of ACh 
release by 15 U/ml IL-2 was a consistent finding even over a 
prolonged period of stimulation. Only tendencies toward de- 
creased or increased values were found for 150 and 0.0 15 mU/ 
ml of IL-2. 
During the first 20 min of K+ stimulation, evoked ACh release 
was modulated by IL-2 in a concentration-dependent manner. 
At 15 U/ml, IL-2 inhibited ACh release by more than 50% of 
the control value. At a 1 OO-fold lower concentration (150 mu/ 
ml), ACh release was only nonsignificantly attenuated (Fig. 2). 
However, when the concentration of IL-2 was further lowered 
to 1.5 mu/ml, an increase in the amount of ACh released by a 
20 min K+ KBM exposure was detected (Fig. 2). No significant 
Table 1. Effect of IL-2 on the evoked release of endogenous ACh 
from hippocampal slices during superfusion 
Time IL-2 (mu/ml) 
(min) 0.0 15 1.5 150 15,000 
O-20 122.2 + 11.5 145.9 ? 26.4 77.1 ? 8.3 44.8 k 15.6 
(n = 10) (n = I)* (n = 9) (n = lo)* 
20-40 115.1 f 15.4 123.2 ?z 7.0 87.8 f 9.1 38.6 f 10.8 
(n = 10) (n = 8) (n = 9) (n = lo)* 
40-60 108.8 k 10.1 96.5 + 16.2 75.9 + 8.7 62.0 k 12.5 
(n = 10) (n = 8) (n = 9) (n = 8)* 
Data are evoked hippocampal ACh release, expressed as percentage of control, 
determined for various periods of tissue exposure to IL-2 in the presence of 25 
rn~ KCI. Release over basal efflux was determined as pmol ACh/min/mg protein. 
Data for slices treated with IL-2 were converted to percentage of the average 
release evoked from control slices. The data for a given concentration represent 
the mean + SEM (n) of two experiments. 
*, P < 0.05. 
* 
* 
* 
-8 -6 -4 -2 0 2 4 
IL-2 [log U/ml] 
Figure 2. Effects of IL-2 on the evoked release of ACh from hippo- 
campal slices. The dose-response curves were obtained from three in- 
tervals during tissue stimulation with 25 mM KC1 (0, O-20 min; 0, 2C- 
40 min; A, 40-60 min). Data are expressed as percentage of control 
measurements carried out in the absence of IL-2. For clarity, error bars 
were omitted, but values are given in Table 1. *, P < 0.05. 
change was observed for the tissue samples treated with 0.0 15 
mu/ml IL-2. 
During the subsequent period of stimulation, that is, the in- 
terval between 20 and 40 min, there was still a marked decrease 
in the evoked ACh release from slices exposed to 15 U/ml IL-2 
(Fig. 2). With lowering the concentration of IL-2, ACh release 
returned to control levels. There was no longer a significant 
increase of evoked transmitter release for IL-2 at 1.5 mu/ml. 
An inhibitory effect of IL-2 was also detected during the in- 
terval between 40 and 60 min of continuous superfusion with 
K+ KBM (Fig. 2). Almost 40% reduction in ACh release was 
found for chambers superfused with 15 U/ml IL-2. However, 
the IL-2 effect was significantly weaker, when compared to the 
period before, that is, the interval between 20 and 40 min (P < 
0.05 in a paired t test) (Fig. 2). Calculated for the total stimu- 
lation period of 60 min, the overall evoked release was (per- 
centage of control) 115.4, 121.9, 80.3, and 48.5 for the exper- 
imental groups treated with 0.0 15 mu/ml, 1.5 mu/ml, 150 mu/ 
ml, and 15 U/ml IL-2, respectively. 
IL-2 also inhibited ACh release when added to an ongoing 
stimulation. As shown in Figure 3, IL-2 at 15 U/ml transiently 
decreased the evoked ACh release when it was added to stim- 
ulated hippocampal slices. The profile returned to control levels 
after 40 min of IL-2 presence, equivalent to 70 min of contin- 
uous stimulation. 
Reversal of the IL-2-mediated inhibition of ACh release 
When hippocampal slices were stimulated with K+ KBM for a 
first period of 30 min (S,) and, following a 30 min rinsing with 
normal KBM, were stimulated a second time (S,, 30 min), the 
amounts of ACh released by S, and S, were identical (1.04 for 
the ratio S,:S,). To test whether the presence of IL-2 during S, 
would alter subsequent ACh release during S, in the absence of 
IL-2, hippocampal slices were exposed to 150 U/ml IL-2 for 30 
min and rinsed for 30 min, before being restimulated. The pro- 
files in Figure 4 show that transient presence of IL-2 did not 
alter the efficacy of later stimulations. Consequently, toxic or 
permanent effects of IL-2 on the tissue could be excluded for 
the duration of the experiments. 
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Figure 3. Effect of IL-2 on an ongoing stimulation of evoked ACh 
release from hippocampal slices. The tissue was stimulated with 25 mM 
KC1 for a total period of 90 min (K+ ); 30 min after the onset of the 
stimulation IL-2 (15 U/ml) was added to the superfusion medium (ar- 
rowhead). Data are given as percentage (mean + SEM, n = 5) of un- 
treated controls. *, P < 0.05. 
Regional d@erences in the effect of IL-2 
Besides the hippocampal formation, IL-2 and IL-2R-associated 
IRM has been localized in a variety of rat brain regions, in- 
cluding the neostriatum and the cerebral cortex (Araujo et al., 
1989; Lapchak et al., 1991). To test whether IL-2 could also 
modulate evoked ACh release in those regions, slices of striatum 
as well as of frontal and parietal cortices were superfused and 
K+ stimulated over 60 min in the absence (controls) or presence 
of IL-2. The results are summarized in Figure 5. The average 
basal release was (in pmol/min/mg protein) 5.94 f 0.84 (n = 
32), 2.56 + 0.48 (n = 27) and 3.27 * 0.64 (n = 21) for the 
striatum, frontal, and parietal cortices, respectively. 
IL-2 at 15 U/ml did not affect evoked ACh release in striatal 
tissue (Fig. 54). The release in the presence of IL-2 was in the 
range between 82.1 f 12.2% and 126.0 + 20.2% when com- 
pared to the corresponding control values. Neither was there 
any effect of IL-2 on slices from parietal cortex; evoked ACh 
was between 90.2 + 16.6% and 98.5 + 13.3% of the corre- 
sponding control level (Fig. 5C). However, 15 U/ml IL-2 re- 
duced the evoked ACh release from frontal cortex during the 
first 20 min of K+ stimulation (Fig. 5B). The evoked release 
during this period was determined to be 49.8 ? 9.9% (n = 5) 
of the control value. 
As was shown for the hippocampus, preexposure to IL-2 did 
not modify the subsequent release pattern in any of these other 
tissues (insets in Fig. 5,4-C). There was thus no evidence for an 
altered transmitter release as a consequence of a previous in- 
cubation of the tissues with IL-2. The striatal evoked ACh re- 
lease during S, (Fig. 5A) was 85.7% of the control amount, and 
108.5% in a second experiment. When compared to the cor- 
responding controls, ACh releases over baseline were 114.0% 
and 93.7% for the S, periods in the frontal and parietal cortices, 
respectively. 
Effects of other cytokines 
The specificity of the IL-2 effect on hippocampal ACh release 
was determined in slice incubations as described in Araujo et 
al. (1989) in the presence or absence (control) of several other 
control control 
-2-i I 
0 40 80 120 
Time [min] 
Figure 4. Evoked hippocampal ACh release following a transient ex- 
posure of the tissue to IL-2. Slices were stimulated for a first period of 
30 min (S,, n = 11) with 25 mM KCl, rinsed for 30 min, and stimulated 
a second time for 30 min (S,). Controls showed identical amounts of 
released ACh for S, and S, (left). Another group of tissue samples (n = 
6) was exposed to IL-2 (150 U/ml) during S,. Following rinsing, the 
tissue was stimulated in the absence of IL-2 (S, shown in the right). 
From the left to the right, the peak areas (corresponding to the amounts 
of released transmitter) were calculated to be lOO.O%, 104.4%, and 
102.8%. Data are given as mean + SEM. 
cytokines. As shown in Table 2, IFNo(, IL-la, IL-3, IL-5, and 
IL-6 did not significantly alter ACh release in this tissue. In 
preliminary experiments, we also observed that rat IL-2, the 
peptide homologous to human IL-2, modulated ACh release at 
50 U/ml. 
Discussion 
The results point to a neuromodulatory action of IL-2 on certain 
populations of cholinergic neurons. At a higher concentration 
(15 U/ml, 5 1 nM), IL-2 showed a pronounced inhibition of 
evoked ACh release in the hippocampus and frontal cortex, 
while being ineffective in the striatum and parietal cortex. In- 
terestingly, a lower concentration of IL-2 (1.5 mu/ml, SO. 1 PM) 
stimulated ACh release in the hippocampal formation. It is thus 
evident that the effect of this cytokine on ACh release is (1) 
concentration dependent and (2) region specific, with terminals 
of selected cholinergic projections (but not striatal intrinsic neu- 
rons) being sensitive to its modulatory activity. 
Modulation of ACh release has been reported for various 
agents, including muscat-uric agonists and antagonists (Raiteri 
et al., 1984; Lapchak et al., 1989) excitatory amino acids (Scat- 
ton and Lehmann, 1982) neurotensin (Lapchak et al., 1990), 
and somatostatin (Araujo et al., 1990). However, micromolar 
concentrations of these agents are required to produce significant 
effects while IL-2 is effective at markedly lower concentrations 
(~0.1 PM) that most likely have physiological relevance. Sim- 
ilarly, sympathetic neurite outgrowth is optimally enhanced by 
0.2-2 U/ml IL-2 (Haugen and Letoumeau, 1990) while neu- 
roendocrine effects of IL-2 were detected using picomolar to 
femtomolar concentrations (Karanth and McCann, 199 1). IL- 
2, in picomolar quantities, is also known to produce soporific 
effects and to modulate EEG spectrum (Nisticb and De Sarro, 
199 1). Higher concentrations (200 to 13000 U/ml) were re- 
quired to block long-term potentiation (LTP) in the rat hip- 
pocampus (Tancredi et al., 1990). 
For the duration of our experiments potential neurotoxic ef- 
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Figure 5. Effects of IL-2 on the evoked ACh release from slices of the 
striatum (A, n = 5), frontal cortex (B, n = 5), and parietal cortex (C, n 
= 6). Tissue slices were stimulated with KBM containing 25 mM KC1 
in the presence (0) or absence (0) of 15 U/ml IL-2. The insets in A-C 
represent the release profiles obtained with 30 min of KC1 stimulation 
from controls (Cl) and from slices following to an exposure to IL-2 (150 
U/ml, 0). Axis dimensions in the insets are the same as in the full-size 
graphs. For further explanation see Results. All data are given as mean 
f  SEM. *, P < 0.05. 
Table 2. K+-evoked ACh release from hippocampal slices incubated 
in the presence of various cytokines 
Hippocampal ACh release 
(“/o of control) 
IFNa (5 nM) 99.8 -t 23.7 (n = 7) 
IL-la (1 nM) 93.3 + 8.2 (n = 8) 
IL-3 (5 nM) 101.9 f  5.3 (n = 10) 
IL-5 (1.3 nM) 93.5 k 4.0 (n = 10) 
IL-6 (5 nM) 95.1 f  6.5 (n = 10) 
Total ACh release during a stimulation of 20 min with 25 rnM KC1 was determined 
and expressed as percentage of the transmitter release from the corresponding 
controls (untreated contralateral hemispheres). The overall control value was 5.95 
k 0.27 pmol/min/mg protein (n = 44). Data are given as mean + SEM. 
fects of IL-2 were not observed, but have been documented in 
neuronal cell culture following a 24 hr exposure to IL-2 (Araujo 
and Cotman, 199 1). In the present series of experiments, sub- 
sequent ACh release during K+ stimulation was not altered by 
previous exposure to IL-2. Furthermore, over prolonged periods 
of stimulation in the presence of IL-2, inhibition of hippocampal 
evoked ACh release attenuated, being significantly less pro- 
nounced or absent after 40 min. In the IL-2RaIIL-2RP receptor 
complex, the a-subunit determines the fast association with IL-2 
(t,,, = 37 set), whereas the p-subunit contributes to the slow 
dissociation of the ligand (t,,Z = 285 min) and to signal trans- 
duction (Kuziel and Greene, 1990; Waldmann, 1991). Similar 
kinetics likely apply in the CNS, the putative k, value (25 PM) 
of 1251-IL-2 binding sites (Araujo et al., 1989) being very low, 
rendering rapid dissociation (“washout”) most unlikely. Taken 
all together, this suggests the termination of the IL-2 signaling 
by endocytosis of the ligandireceptor complex (Legrue et al., 
1991). As shown in YT+ cells, lZ51-IL-2 is almost completely 
internalized after 30-40 min incubation period (Fung et al., 
1988). 
While IL-2 was shown to be a very potent modulator of hip- 
pocampal ACh release, several other cytokines with established 
CNS activities (Plata-Salaman, 199 l), that is, IFNq IL- lol, IL- 
3, IL-5, IL-6 (in the present study), and IL-l& as well as IL-4 
(in Araujo et al., 1989) were ineffective, indicating that ACh 
release in the hippocampus is sensitive to a specific effect of 
IL-2 that is not shared by other well-known cytokines. 
IL-2(-like) and IL-2R-associated (Tat antigen-like) IRM are 
present in the rat hippocampal formation, especially in the stra- 
tum pyramidale of the hippocampus proper as well as in the 
granule cell layer of the dentate gyrus (Lapchak et al., 199 1). It 
is well known that cholinergic septal projections terminate 
throughout the hippocampal region, but most heavily in the 
strata oriens and radiatum of subfields CA2 and CA3, as well 
as in the infra- and supragranular zones of the dentate gyrus, 
making contacts with pyramidal and granule cell bodies and 
dendrites (Semba and Fibiger, 1989). The proximity of IL-2- 
related IRMs and cholinergic terminals is very striking and may 
thus explain our functional observation, that is, the modulation 
of ACh release by the cytokine in the hippocampal formation. 
On the other hand, IL-2/IL-2R-like IRM in the frontoparietal 
cortex concentrates within layer IV, with the staining decreasing 
in more caudal and ventral cortical areas (Lapchak et al., 199 1). 
In the rat, cholinergic fibers innervating the frontoparietal cortex 
originate from cells in the vicinity of the substantia innominata 
and the ventromedial globus pallidus (Semba and Fibiger, 1989). 
Although some intrinsic ACh neurons exist in the cortex (layers 
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II/III), the laminar pattern of cholinergic terminals predomi- 
nantly arises from these projections, with high densities seen in 
layer V, and to a lesser extend in layer IV. It thus appears that 
most prominent effects of IL-2 on ACh release were observed 
in cortical and hippocampal areas that contain cholinergic pro- 
jection terminals in proximity to IL-2/IL-2R IRM. 
In contrast, IL-2 failed to modulate ACh release in the stria- 
turn, an area enriched with ACh interneurons (l-2% of the cells; 
Semba and Fibiger, 1989) and detectable quantities of IL-YIL- 
2R IRM (Lapchak et al., 199 1). This illustrates that IL-2 is not 
a universal modulator of ACh release, but exerts its effects in 
regions where IL-2-related IRM was localized in vicinity to the 
terminals of far-projecting ACh neurons. 
The modulatory effect of IL-2 on ACh release, especially in 
the hippocampus, is of potential interest in regard to the im- 
pairments of cholinergic functions in Alzheimer’s disease (AD) 
(Whitehouse et al., 1982; Quirion et al., 1990). In that context, 
it is intriguing that cholinergic neurons of the striatum, an area 
usually spared in AD, are insensitive to IL-2. It is also known 
that various markers of the immune system, such as major 
histocompatibility complex glycoproteins, immunoglobulin, 
complement, and cytokine receptors, infiltrating T-cells, cyto- 
kines, and complement factors, associated with neurodegener- 
ative plaques and neurofibrillary tangles, are present in AD 
brains, implicating immune-mediated autodistruction as an im- 
portant pathological event in this disorder (McGeer and Rogers, 
1992). IL-2, though not being the sole candidate, could play a 
crucial role in the central cascading of immune-related markers, 
as it does in the periphery. 
Regarding the biphasic profile of action observed in the hip- 
pocampus, IL-2, normally expressed in low amounts, could usu- 
ally stimulate ACh release. However, under pathological con- 
ditions, levels of IL-2 are likely increased (McGeer and Rogers, 
1992) and could conceivably contribute to decreased levels of 
ACh released by terminals especially in the regions primarily 
affected in AD, such as the hippocampus and the frontal cortex. 
High concentrations of IL-2 are known to interfere with LTP 
in the hippocampus (Tancredi et al., 1990) an observation that 
could also relate to neurologic side effects associated with high- 
dose IL-2 immunotherapies (Denicoff et al., 1987; Plata-Sala- 
man, 199 1). 
Bidirectional communication between the immune system 
and the CNS is likely mediated by both direct cellular contacts, 
for example, via innervation of immunocompetent organs, and 
soluble factors triggering effects in remote tissues or providing 
humoral feedbacks (Bateman et al., 1989; De Micco, 1989; Dunn, 
1989; Jankovic, 1989; Rabin et al., 1989; Stemberg, 1989; Mer- 
rill, 1990; Plata-Salaman, 1991). Some of these mediators can 
be produced by cells of both systems, obliterating the “classical” 
demarcation between immuno- and neuroregulators. Immu- 
noregulators likely play pivotal roles in normal CNS develop- 
ment and function, in the induction and coordination of post- 
traumatic events (Plata-Salaman, 1991; Hall and Rao, 1992) 
and probably in pathogenetic processes associated with neuro- 
logic disorders (Blume and Vitek, 1989; Matsuyama et al., 199 1; 
Vandenabeele and Fiers, 1991; McGeer and Rogers, 1992; 
Royston et al., 1992). Upon challenge of an immune or inflam- 
matory response or during cytokine-based immunotherapy, cy- 
tokines may become more active in the CNS, provided that they 
have access to functionally coupled receptors in the brain. In 
the case of IL-2, evidence has been reported that fulfills these 
predictions. However, it remains to be shown whether other 
factors known to be induced by IL-2, such as tumor necrosis 
factor, are partly responsible for effects ascribed to IL-2 (Ellison 
and Merchant, 1991). It is thus of great interest to determine 
whether the modulatory action of this cytokine on cholinergic 
nerve terminals is due to a direct effect or whether it involves 
other mediators. 
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